Search research articles
Contact Us
Filters
Showing results (1-10 of 101) with videos related to
Page
of 11
Sort By:
Expert Review of Neurotherapeutics
|
July 5, 2011
Pramipexole for the treatment of early Parkinson's disease
Santiago Perez-Lloret, Santiago Perez Lloret, María Verónica Rey, et al.
Expert Opinion on Pharmacotherapy
|
February 26, 2009
Rotigotine transdermal delivery for the treatment of Parkinson's disease
Olivier Rascol, Santiago Perez-Lloret
Expert Opinion on Drug Safety
|
April 2, 2011
Safety of rasagiline for the treatment of Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
CNS Drugs
|
October 12, 2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy
|
July 31, 2010
Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease
Santiago Perez Lloret, Olivier Rascol
Expert Review of Neurotherapeutics
|
February 6, 2016
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
CNS Drugs
|
June 27, 2016
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease
Santiago Perez-Lloret, Olivier Rascol
Journal of Neural Transmission (Vienna, Austria : 1996)
|
March 8, 2018
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia
Santiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy
|
March 29, 2014
Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant
Santiago Perez-Lloret, Marcelo Merello
NPJ Parkinson'S Disease
|
July 21, 2017
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease
Santiago Perez-Lloret, Francisco J Barrantes
Page
of 11
Search research articles
Search
Showing results (1-10 of 101) with videos related to
Sort By:
Page
of 11
Expert Review of Neurotherapeutics
|
July 5, 2011
Pramipexole for the treatment of early Parkinson's disease
Santiago Perez-Lloret, Santiago Perez Lloret, María Verónica Rey, et al.
Expert Opinion on Pharmacotherapy
|
February 26, 2009
Rotigotine transdermal delivery for the treatment of Parkinson's disease
Olivier Rascol, Santiago Perez-Lloret
Expert Opinion on Drug Safety
|
April 2, 2011
Safety of rasagiline for the treatment of Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
CNS Drugs
|
October 12, 2010
Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy
|
July 31, 2010
Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease
Santiago Perez Lloret, Olivier Rascol
Expert Review of Neurotherapeutics
|
February 6, 2016
The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease
Santiago Perez-Lloret, Olivier Rascol
CNS Drugs
|
June 27, 2016
Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease
Santiago Perez-Lloret, Olivier Rascol
Journal of Neural Transmission (Vienna, Austria : 1996)
|
March 8, 2018
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia
Santiago Perez-Lloret, Olivier Rascol
Expert Opinion on Pharmacotherapy
|
March 29, 2014
Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant
Santiago Perez-Lloret, Marcelo Merello
NPJ Parkinson'S Disease
|
July 21, 2017
Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease
Santiago Perez-Lloret, Francisco J Barrantes
Page
of 11